Mutiny At Aurinia Pharmaceuticals? Biotech Rallies On C-Suite Shake-Up

Aurinia Pharmaceuticals (AUPH) announced a complete overhaul of its C-suite on Monday, sparking a rally in the biotech stock and igniting hopes that an acquisition could be in the offing.

Kevin Tang, who leads hedge fund Tang Capital Management, has been appointed chief executive, taking over from Peter Greenleaf, who has led the company for seven years. Tang has been the chair of Aurinia’s board of directors since 2024.

				    ↑
					X

This video file cannot be played.(Error Code: 102630)

								China's 'Cutthroat' Biotech Industry Is Booming. Can Western Companies Still Compete?
							

							

								See All Videos
							

						

					
					
						NOW PLAYING
						China's 'Cutthroat' Biotech Industry Is Booming. Can Western Companies Still Compete?

Tang has a “proven operational track record” and has led “multiple companies through successful exits,” RBC Capital Markets analyst Douglas Miehm said in a report. That includes Ardea Biosciences before AstraZeneca (AZN) bought it in 2012 and La Jolla Pharmaceutical prior to its Innoviva (NVA) takeover in 2022.

“Tang has used Concentra Biosciences as a vehicle to often target struggling biotech companies, where some sort of transaction is the end goal,” Leerink Partners analyst Joseph Schwartz said in a report. “Now that Tang has taken the helm at Aurinia, which is a commercial business with positive cash flow, it will be interesting to learn what concrete plans he and his team have for the company.”

Aurinia Pharmaceuticals’ New C-Suite

Aurinia stock jumped 3.9%, closing at 14.56. The biotech stock is consolidating with a buy point at 16.54, according to MarketSurge. Monday’s move pushed Aurinia stock briefly above its 50-day moving average. Shares closed in line with that key mark.

In addition to Tang’s appointment as CEO, Ryan Cole was appointed chief operating officer, Michael Hearns will take over as chief financial officer, and Thomas Wei was named chief scientific officer. All three have ties to Tang Capital Management, Leerink’s Schwartz said.

He kept his market perform rating on the biotech stock, but noted he looks “forward to learning more about the new team’s plans to enhance shareholder value.”

The timing of the executive changes is “curious,” he said. The previous management team planned to provide an update on development plans for aritinercept in the next quarter. Aritinercept is being developed to treat autoimmune diseases. Aurinia also sells Lupkynis, a treatment for lupus nephritis.

‘Slightly Positive’ For Biotech Stock

RBC’s Miehm is more bullish on the changes, saying they are “slightly positive” for the biotech stock.

Tang already owns roughly 9% of Aurinia Pharmaceuticals’ outstanding shares, aligning his interests with shareholders’ interests more broadly. Tang has also decided to forgo all compensation as CEO. Further, the other executives are coming in with lower salaries than their predecessors. This signals cost discipline.

“While the simultaneous departure of four senior officers introduces near-term executive risk, Tang’s hands-on involvement and capital commitment suggest a focused strategy for value realization,” he said.

Miehm rates the biotech stock a sector perform with a 15 price target.

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

		SIGN UP NOW!

IBD Newsletters

Get exclusive IBD analysis and actionable news daily.

										*   							
								How To Invest								
								
							
						
										*   							
								Market Prep								
								
							
						
										*   							
								Tech Report								

Please enter a valid email address

Please select a newsletter

			GO

Get these newsletters delivered to your inbox & more info about our products & services. Privacy Policy & Terms of Use

		x

Thank You!

You will now receive IBD Newsletters

			ALL DONE!

Something Went Wrong!

Please contact customer service

			CLOSE

Follow Allison Gatlin on X/Twitter at @AGatlin_IBD.

YOU MAY ALSO LIKE:

Rhythm Grabs A New Obesity Approval; How It Edged In Where Lilly, Novo ‘Have Fallen Flat’

How Apogee, Up 14%, Plans To Take On Rival Regeneron’s Eczema Drug

Looking For The Next Big Stock Market Winners? Start With These 3 Steps

See IBD Stock Lists & Get Pass/Fail Ratings For All Your Stocks With IBD Digital

IBD Stock Of The Day: See How To Find, Track And Buy The Best Stocks